新诊断T1高级别膀胱尿路上皮癌的治疗策略:新见解与更新推荐
该指南基于系统综述更新T1HG膀胱癌治疗推荐:再次TUR后,选择保膀胱者行BCG诱导加维持,高危特征者考虑即刻膀胱切除,BCG难治/无反应者应早期膀胱切除。
要点
- T1HG初诊TUR后推荐再次TUR以降低分期不足风险。
- 保膀胱方案为BCG诱导后维持治疗。
- BCG难治或无反应者应考虑早期膀胱切除。
核心结论
- T1HG肿瘤异质性强,治疗具有挑战性。
- BCG诱导加维持的保膀胱治疗或根治性膀胱切除是当前标准治疗选择。
- BCG无反应疾病的有前景疗法正在研究中。
主要发现
- 初诊TUR时临床分期不足和/或疾病持续存在并不少见。
- 选择保膀胱方案的患者应接受BCG诱导治疗后维持方案。
- 具有多个高危特征的患者应考虑即刻膀胱切除。
- BCG难治或无反应疾病患者应考虑早期膀胱切除。
关键数值与推荐
- 推荐对T1HG膀胱癌病例行再次TUR。
- 保膀胱治疗包括BCG诱导和维持。
- 高危特征患者考虑即刻膀胱切除。
- BCG难治或无反应者考虑早期膀胱切除。
临床怎么用
- 对T1HG患者,初诊TUR后应行再次TUR评估。
- 与患者讨论保膀胱(BCG诱导加维持)与根治性膀胱切除的利弊。
- 识别高危特征和BCG反应状态以指导早期膀胱切除决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: High-grade T1 (T1HG) bladder cancer (BCa) has a very high likelihood of disease recurrence and progression to muscle invasion. Radical cystectomy is considered the best chance at cure, albeit with a high risk of morbidity, and is overtreatment for some patients. Treatment with bacillus Calmette-Guerin (BCG) allows bladder preservation but may risk disease progression. OBJECTIVE: To systematically review the current literature on the management of T1HG BCa and provide updated treatment recommendations. EVIDENCE ACQUISITION: Medline, EMBASE, and Epub Ahead of Print databases were searched in November 2017 to identify observational cohort studies and controlled trials, between 1946 and 2017, associated with diagnosis, treatment, and prognosis of T1HG BCa. EVIDENCE SYNTHESIS: Clinical understaging and/or persistence of disease is not uncommon at initial transurethral resection (TUR); thus, a second re-TUR is recommended for cases with T1HG BCa. Patients electing a bladder preservation approach should undergo induction BCG therapy followed by a maintenance schedule, while patients with several high-risk features should consider immediate cystectomy and those with BCG-refractory or BCG-unresponsive disease should be considered for early cystectomy. Current phase I/II clinical trials for T1HG patients may offer future bladder preservation therapy approaches. CONCLUSIONS: T1HG tumours are heterogeneous in nature and challenging to treat. Bladder preservation with BCG induction and maintenance, or radical cystectomy is the current standard treatment modality of choice for these tumours. Promising therapies for BCG-unresponsive disease are currently under investigation. PATIENT SUMMARY: Patients with high-grade T1 bladder cancer are at a high risk of tumour recurrence and progression, requiring more aggressive treatment such as bladder removal. Bladder preservation therapies are available (and new therapies are being tested in clinical trials); however, patients should be aware that currently bladder removal is considered the best opportunity for cancer cure.
引用
- Klaassen Z, Kamat AM, Kassouf W, et al. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. Eur Urol. 2018. PMID: 30017405. doi:10.1016/j.eururo.2018.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。